Indication intelligence, analysis and sector perception

RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results

March 29, 2024

A scorecard of earnings releases of covered companies -  The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 29 of 35 covered released to date    

RegMed Investors (RMi) research note – Finance: Sangamo Therapeutics (SGMO) Proposes Offering of 24,761,905 shares priced at $0.84

March 22, 2024

SGMO dived $0.1465 to $08238 or -15.098% And pre-funded warrants of 3,809,523 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of common stock priced at $0.83 Gross proceeds $24 M possible Barclays and Cantor are acting as placement agents for the offering

RegMed Investors (RMi) Research Note - Finance: Fate Therapeutics (FATE) prices a private placement and underwritten offering of 14,545,454 shares at $5.50 per share.

March 19, 2024

FATE opened +$0.10 to $7.14 In addition, Fate priced a concurrent private placement of pre-funded warrants to purchase 3,636,364 shares of its common stock at a purchase price of $5.499 per pre-funded warrant, to certain institutional and other accredited investors affiliated with or managed by Redmile Group, LLC. The offering includes participation from new and existing institutional investors: Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.